Binding Kinetics and Mechanistic PK/PD modeling in early Drug Discovery

A two-day meeting hosted by the British Pharmacological Society and AstraZeneca in Cambridge. Early bird registration end 20 January 2023.

27-28 March 2023  |  Cambridge, UK

The British Pharmacological Society and AstraZeneca are delighted to announce the focused meeting: Binding Kinetics and Mechanistic PK/PD modeling in early Drug Discovery. The meeting is to be held over two days in Cambridge, UK. Registration for the meeting includes lunch and light refreshments on both days.

Meeting topics

This event aims to bring together established leaders and emerging investigators exploring the use of binding kinetics in guiding early drug discovery.

  • Small molecule-target Binding kinetics

  • Mechanistic PK/PD (Pharmacokinetics/Pharmacodynamics) modelling

  • Early Drug Discovery

Learning outcomes

Our expectation is that the meeting may serve:

  • A special themed issue to published from the deliberations of this meeting

  • Establishing the framework for the implementation of kinetics in drug discovery

  • Attempts at establishing guidelines on the uniform nomenclature for this field to avoid ambiguities

CPD points

CPD points from the Royal College of Physicians and Royal Society of Biology are available at this meeting. You will be emailed a certificate of attendance with CPD points after the meeting.

Binding Kinetics and Mechanistic PK/PD modeling in early Drug Discovery

You can download a copy of the programme here.

DAY 1: Binding and Enzyme Kinetics in early Drug Discovery

09:30-09:55         Registration and refreshments 

09:55-10:00         Welcome & introduction: Bharath Srinivasan & Jonathan Wingfield

10:00-10:15         Opening Remarks: Mike Snowden, SVP, Discovery Sciences

                                 Session Chair: Amaury Fernández-Montalván

       10:30-11:25        Opening plenary: Dr Robert Copeland   
                                 Evolution of the Drug-Target Residence Time Model in Drug Discovery

       11:25-12:05        Steven Charlton                              
       12:05-12:20        Oral Communication OC01: Chendi Gu                                       
                                 Distinct mechanisms to target SARM1 for treating axon degeneration

       12:20-13:30        Lunch & Poster Viewing

                                  Session Chair: Geoff Holdgate

       13:30-14:10        Rachel Grimley                                 
                                               Mechanistic Insight in Drug Discovery: “Elephant” or “Unicorn”?

       14:10-14:25        Oral Communication OC02: Kevin Dalby                                      
                                 Development of covalent inhibitors of ERK docking interactions

       14:25-15:05        Margaret Porter Scott                      
                                 Impact of drug binding kinetics across large and small molecules at Genentech

        15:05-15:30       Refreshment break

                                 Session Chair: Argyrides Argyrou

         15:30-15:50      Partner Session: Enzymologic - Ana Corrionero 
Kinetic profiling of reversible and irreversible inhibitors at speed and scale

         15:50-16:05      Oral Communication OC03: Sarah Folliet                                    
                                  Understanding cellular potency by Motulsky-Mahan kinetic profiling of compounds in the absence of a direct binding assay

         16:05-16:20      Oral Communication OC04: Claire McWhirter                             
                                               Kinetic and Mechanistic Characterisation of Polθ Inhibitors

         16:20-17:00       Steve Hill                                          
                                  Kinetic analysis of fluorescent ligand binding to investigate conformational changes and allosterism in living cells

       17:00-17:30        Poster Presentation 
       17:30- 19:00       Drinks Reception


DAY 2: Mechanistic PK/PD Modelling in Early Drug Discovery

09:00-9:15          Welcome Remarks: Bharath Srinivasan & Jonathan Wingfield

09:15-9:30          Opening Remarks: Steve Rees, VP, Discovery Biology, AstraZeneca

                                  Session Chair: Thomas Lundback

09:30-10:10       Adriaan Ijzerman                             
                         Target binding kinetics and G protein-coupled receptors

10:10-10:25       Oral Communication OC05: Samuel Hoare                              
                         Quantifying the kinetics of G-protein-coupled receptor signaling using high performance biosensors and a simple curve fitting data analysis package

10:25-10:40       Oral Communication OC06: Benjamin Read                       
                          Dissecting the Kinetic Partition of Inhibitor Binding to Acinetobacter baumannii ATP Phosphoribosyltransferase Through Transient-State Kinetics

10:40–11:00       Partner Session: AssayQuant - Earl May 

                           Monitoring Continuous Enzyme Activity with Fluorogenic Sensor Assays Enables Data-Rich Decisions for Improved Kinase & Phosphatase Drug Discovery
11:00-11:30       Refreshment break

                         Session Chair: Bharath Srinivasan

11:30-11:45       Oral Communication OC07: Sofia Guzzetti                                  
                          An integrated modelling approach for targeted degradation: optimisation, data requirements and PKPD predictions from mechanistic models and exact solutions

11:45-12:00       Oral Communication OC08: Jonathan Bailey                             
                         Different ligands binding at the same allosteric site have drastically diverse effects on the activity of human Mat2A

12:00-12:40       Piet van der Graaf                           
                         Translating binding kinetics from in vitro pharmacological property to therapeutic benefit using mechanistic PKPD modelling

12:40-13:40      Lunch & Poster viewing

                       Session Chair: Andrea Gohlke

13:40-14:20     Elisabeth Lange                               
                       On in vivo binding kinetic modelling approaches

14:20-15:00       Daniel Thomas                                
                        Digitised Drug Discovery and the future of kinetics

15:00-15:30       Refreshment break
                         Session Chair: Stefan Geschwindner

15:30-16:25       Closing plenary: Peter Tonge             
                          Widening the Therapeutic Window: Kinetic Selectivity and Target Vulnerability

16:25-16:45       Best Oral Presentation and poster award: Maria Flocco, VP, MSB

16:45-17:00       Closing remarks: Maria Flocco, VP, MSB
17:00                 End of meeting


Dr Robert Copeland
Accent Therapeutics, United States of America 

Talk title: Evolution of the Drug-Target Residence Time Model in Drug Discovery

Robert A. Copeland, Ph.D. founded Accent Therapeutics, Inc. in September2017 and serves as its President and Chief Scientific Officer. He is also President of the independent consulting firm, Ki Consultant, LLC. He was formerly President of Research andChief Scientific Officer of Epizyme, Inc. and before that, Vice President of Cancer Biology, Oncology Center of Excellence in Drug Discovery, GlaxoSmithKline. Dr. Copeland serves on a number of advisory boards within industry, academia, professional societies and professional journals. Hereceived his B.S. in chemistry from Seton Hall University, his doctorate in chemistry from Princeton University and did postdoctoral studies as the Chaim Weizmann Fellow at the California Institute of Technology. His research interest is in elucidating the determinants of drug recognition by their biological targets and the use of this information in the discovery and design of new medicines. He has contributed to drug discovery and development efforts leading to 19 investigational new drugs entering human clinical trials. These include the cancer drugs Tazverik™(tazemetostat), Tafinlar™(dabrafenib) and Mekinist™(trametinib), the anemia drug Duvroq™(daprodustat) and the antibiotic Altabax™(retapamulin). Dr. Copeland has contributed more than 200 publications to the scientific literature, holds 14 issued U.S. patents and has authored 5 books in the areas of protein science and enzymology.In 2016 he waselected a Fellow of the American Association for the Advancement of Science (AAAS) and in 2020 he was elected a Fellow of the Royal Society of Chemistry.


Dr Adriaan Ijzerman
Leiden University, Netherlands 

Talk title: Target binding kinetics and G protein-coupled receptors

Ad IJzerman is emeritus professor of medicinal chemistry at the Leiden Academic Centre for Drug Research of Leiden University. He is an expert on drug targets, in particular G protein-coupled receptors (GPCRs). His team focuses on concepts in GPCR drug discovery and pharmacology, such as partial agonism, inverse agonism and constitutive activity, allosteric modulation and target binding kinetics. As he sees it, the challenge is to link these pharmacological principles with structural biology, i.e. to unravel the molecular features of ligand and receptor that govern these paradigms. He has been involved in the structure elucidation of a number of GPCRs, including one of the first, i.e. the adenosine A2A receptor, which has become a citation classic (Science, 2008). Later his team was part of a collaborative effort to successfully determine the structure of the chemokine CCR2 receptor (Nature, 2016), providing evidence for the presence of two antagonists at the same time in the receptor architecture. He has been nominated Highly Cited Researcher over the past few years. In terms of leadership Ad has contributed significantly to the field of medicinal chemistry. He led a number of European research consortia, including on adenosine receptors, inverse agonism and target binding kinetics, where industry and academic partners share the privilege of advancing novel concepts in drug discovery.


Dr Elizabeth de Lange
Leiden University, Netherlands 

Talk title: On in vivo binding kinetic modelling approaches

Elizabeth de Lange, PhD, is Professor of Predictive Pharmacology at the Division of Systems Pharmacology and Pharmacy of the Leiden Academic Centre for Drug Research (LACDR) at Leiden University in the Netherlands. She combines advanced multi-level experiments and analytical techniques to produce smart data, and mathematical modelling, as a unique approach to build robust mathematical models for the prediction of drug effects in human, which is the ultimate aim of her research.
In the development of mathematical models that predict pharmacokinetic (PK)- pharmacodynamic (PD) relationships in human, in health and disease, she involves identification and characterization of key factors as well as their interdependencies. Particular emphasis lies on investigations on target tissues protected by special barriers, like the central nervous system (CNS).
This research has a comparative and integrative design to elucidate conditional influences of individual factors to the whole (Mastermind research Approach). This is a crucial basis for translation between species and conditions. A recent success is the development of a physiologically-based CNS PK model that is able to adequately predict drug distribution into and within multiple compartments of the rat and human CNS. Another highlight is the contribution to understanding the in vivo context of drug target residence time to predict the effects of drugs.
She has published >145 papers, has provided >150 invited lectures, and has (co-)organized > 85 scientific meetings. In 2013, she received the AAPS Fellow Award. In 2020, she received an Honorary doctorate from Uppsala University. Also in 2020 she received the Lewis Sheiner lecture award from the International Society of Pharmacometrics for her life time achievements in modelling and simulation.


Dr Piet van der Graaf 
Leiden University, Netherlands 

Talk title: Translating binding kinetics from in vitro pharmacological property to therapeutic benefit using mechanistic PKPD modelling

Piet van der Graaf is Senior Vice President Quantitative Systems Pharmacology at Certara (UK) and Professor of Systems Pharmacology at Leiden University (The Netherlands). From 2013-2016 he was the CSO of the Leiden Academic Centre for Drug Research. From 1999-2013 he held various leadership positions at Pfizer in Sandwich (UK) in Discovery Biology, Pharmacokinetics and Drug Metabolism and Clinical Pharmacology. He was the founding Editor-in-Chief of CPT: Pharmacometrics & Systems Pharmacology from 2012-2018 before becoming Editor-in-Chief of Clinical Pharmacology & Therapeutics. Piet received his doctorate training in clinical medicine with Nobel laureate Sir James Black at King's College London and was the recipient of the 2021 Leadership Award from the International Society of Pharmacometrics (ISoP). He is a Fellow of the British Pharmacological Society.


Dr Peter Tonge
Stony Brook University, United States of America 

Talk title: Widening the Therapeutic Window: Kinetic Selectivity and Target Vulnerability

Dr. Tonge is a Distinguished Professor of Chemistry and of Radiology (by courtesy) at Stony Brook University, where he is the Chair of the Department of Chemistry, and Director of the Center for Advanced Study of Drug Action. He is also an Associate Editor for ACS Infectious Diseases. Dr. Tonge earned his B.Sc. and Ph.D. degrees in Biochemistry from Birmingham University, UK, and was a SERC/NATO post-doctoral fellow in the Division of Biological Sciences at the National Research Council of Canada (NRCC). After positions as a Research Associate and Research Officer at NRCC, he was a Staff Investigator at the Picower Medical Research Institute before joining Stony Brook University. His awards include an Alfred P. Sloan Research Fellowship in 2000, and a Fellowship from the Pharmaceutical Research and Manufacturers of America (PhRMA) in 2017 which funded a sabbatical at Genentech.


Dr Daniel Thomas
Arctoris, United Kingdom

Talk title: Digitised Drug Discovery and the future of kinetics

Dr Daniel Thomas is an experienced drug discovery professional with over 20 years in early stage R&D across pharma and biotech. He has extensive theoretical and practical knowledge of assay development, molecular profiling and enzyme kinetics and is an accomplished leader with a track record of developing trans-national matrix research teams. As Head of Discovery Biology, he is responsible for the development and implementation of a comprehensive scientific strategy designed to deliver the best in data quality. Combining a world-class team of engineers and drug discovery experts, Arctoris has developed the world’s first fully automated drug discovery platform, Ulysses. Together with pharma, biotech and AI drug discovery companies, Arctoris deploys this platform generating research data at unprecedented quality and speed, building unique data resources for machine learning applications around the globe. Combining the latest laboratory techniques with advanced robotics and AI, Arctoris brings drug discovery into the digital age.


Professor Steven Charlton
OMass Therapeutics and University of Nottingham, UK

Talk title: How the kinetics of target binding and rebinding influences drug efficacy

Steven Charlton is Vice President, Pharmacology at OMass Therapeutics, a company utilising high-resolution native mass spectrometry to drive drug discovery. Prior to that he was co-founder and CSO at Excellerate Bioscience, a CRO providing specialist molecular pharmacology support to the pharmaceutical industry. Steven has over 20 years drug discovery experience, with previous roles at both SmithKline Beecham and Novartis. At Novartis he was Director of the Molecular Pharmacology Unit in Respiratory Diseases, responsible for compound profiling across a broad range of drug targets. He also served on development teams covering late clinical development through post-launch. In 2007 Steven was awarded Novartis Leading Scientist in recognition of his contribution to the field of quantitative pharmacology and to the Novartis pipeline. Steven is currently also Professor of Molecular Pharmacology and Drug Discovery in the School of Life Sciences at Nottingham University, and a Fellow of the British Pharmacological Society. He is interested in all aspects of the quantitative assessment of ligand-receptor interactions, with a particular interest in the kinetics of ligand binding and signalling.

Dr Rachel Grimley
Cancer Research Horizons, Cancer Research UK

Talk title: Mechanistic Insight in Drug Discovery: “Elephant” or “Unicorn”?

Rachel is Senior Vice President of Drug Discovery for Cancer Research Horizons, Cancer Research UK. Rachel has over 20 years’ experience in pre-clinical drug discovery, incorporating target identification through to drug candidate nomination, across a number of companies. She has contributed to the discovery and characterisation of numerous drug candidates, and 3 marketed medicines, across a diverse range of disease areas including oncology, neuroscience, respiratory, cardiovascular and anti-infectives.
Rachel is also an Expert-in-Residence at the University of Oxford.
Prior to joining Cancer Research Horizons in 2021, Rachel was Executive Director and Head of Mechanistic Biology & Profiling at AstraZeneca, with global responsibility for in vitro mechanism of action studies, SAR biology profiling, Wave1 DMPK and pre-clinical safety screening across the UK, US and Sweden. Previously, Rachel held roles of increasing responsibility at Pfizer in Sandwich, GlaxoSmithKline in Stevenage and Pfizer Neusentis in Cambridge.
Rachel gained her PhD in Mechanistic Enzymology from the University of Birmingham and completed post-doctoral studies at the University of Oxford.

Dr Margaret Porter Scott
Vice President, Genentech, UK 

Talk title: Impact of drug binding kinetics across large and small molecules at Genentech

Dr. Margaret Porter Scott is Vice President of Biochemical and Cellular Pharmacology at Genentech. She and her team bring expertise in quantitative in vitro assays and the mechanistic study of molecules to all of Genentech’s research programs across all therapeutic areas and all modalities. Previous to joining Genentech, Margaret was the first employee of Epizyme rising to Senior Director of Lead Discovery and was instrumental in delivering several first-in-human inhibitors including the approved drug Tazemetostat for the treatment of epithelioid sarcoma. Prior to Epizyme, Margaret had over a decade of training in drug discovery through her scientific positions at Millennium, Neogenesis, Vertex and Pfizer. Margaret received her BA from Oberlin College and her PhD from SUNY Stony Brook.

Professor Steve Hill
University of Nottingham, UK

Talk title: Kinetic analysis of fluorescent ligand binding to investigate conformational changes and allosterism in living cells

Professor Steve Hill is Professor of Molecular Pharmacology in the School of Life Sciences, University of Nottingham. He was the inaugural Co-Director of University of Birmingham and University of Nottingham Centre of Membrane Proteins and Receptors (COMPARE) from 2016-2021 and was President of the British Pharmacological Society from 2018-2019. Steve obtained his first degree in pharmacology at the University of Bristol and his PhD (pharmacology) at the University of Cambridge. His research has concentrated mainly on the molecular pharmacology of cell surface receptors (particularly G protein-coupled receptors [GPCRs] but more recently receptor tyrosine kinases and cytokine receptors). Currently, the emphasis of his work is on the study of kinetics of ligand-receptor interactions in single living cells using a variety of fluorescent imaging techniques including fluorescence correlation spectroscopy, confocal imaging, CRISPR/Cas9 genome editing and resonance energy transfer techniques. In particular, he is interested in the cooperative interactions (positive and negative) between the protomers of receptor dimers, the influence of small molecule allosteric regulators on orthosteric ligand binding and signalling and the potential for protein-protein interactions between receptors and associated co-receptors and signalling proteins. He joined the University of Nottingham in 1981 and was subsequently promoted to Reader (1989) and Professor of Molecular Pharmacology (1995). In 1997, he became Director of the Institute of Cell Signalling and in 2008 Head of the School of Biomedical Sciences (until 2013). He was a founding director of the University of Nottingham spin-out company CellAura Technologies Ltd that provided fluorescent ligands to the scientific community until it was acquired by HelloBio in 2014. Steve is also a previous Chair of the MRC Molecular and Cellular Medicine Board. His work is currently funded by MRC and the EU ITN ONCORNET2.0. Steve was awarded the 2018 Vice Chancellor’s Medal from the University of Nottingham and the 2019 Ariens Award from the Dutch Pharmacological Society for outstanding contributions to pharmacology.

To view the full list of speakers and chairs, please visit our programme


Dr Mike Snowden
Senior Vice President at AstraZeneca

Dr Mike Snowden is a Senior Vice President at AstraZeneca leading the Discovery Sciences department within R&D Biopharmaceuticals and is responsible for delivering a world-class portfolio of drug discovery projects from identification of novel targets with AZ Therapy Areas through to candidate selection, with enhanced probability of success at proof of concept.

Mike joined AstraZeneca 9 years ago after more than 25 years in preclinical science. Graduating as a biochemist, with a PhD and postDoc in molecular biology, Mike started his Pharmaceutical career in anti-infectives, moving to Cardiovascular, Respiratory and then Neuroscience drug discovery where he was the principle enzymologist and kineticist in a number of novel drug discovery targets.

After a 2-year appointment as Head of Business Development and Outsourcing for the pre-clinical organization at GSK, Mike joined AZ as Head of Head of Discovery Sciences. Discovery Sciences is a preclinical department, focused on providing core scientific capabilities across all therapy areas in AZ.

Mike has very wide research interests including structural and biophysical technology platforms for discovery and he is currently focusing on advances in gene editing technologies for pre-clinical and clinical use.


Dr Maria Flocco
Vice President, Mechanistic and Structural Biology

Maria joined AstraZeneca in 2015 as head of Structure and Biophysics moving to her current role in 2021. Previous to joining AstraZeneca, she held various positions of increasing responsibility in Pfizer and Pharmacia. She was Senior Director and Head of External R&D Innovation Europe, Sr Dir Head of Internal Medicine Chemistry, Sr Dir Head of Lead Discovery, and Director Head of Structural Biology and Biophysics at Pfizer, and Head of Structural Chemistry at Pharmacia. Prior to her career in the pharmaceutical industry, Maria was a Lecturer at the Karolinska Institute, Stockholm, and a researcher at the Uppsala Biomedical Centre, Sweden.

Maria received a PhD in Physical Chemistry from the City University of New York, and postdoctoral training in X-ray crystallography at the Fox Chase Cancer Centre, Philadelphia, and the Uppsala Biomedical Centre.

Maria has established successful external collaborations and is currently a member of the scientific advisory panel of the Rosalind Franklin Institute, Oxford. She has been a member of the MRC Molecular and Cellular Medicine Board, the SAB of INSTRUCT EU, the SAB of the Chemical Biology Institute of Imperial College London and the SAB of INSERM Transfert Initiative, a seed funding organisation of INSERM in France.


Dr Steve Rees
Vice President, Discovery Biology

Steve is Vice-President of Discovery Biology at AstraZeneca with responsibility for reagent generation and assay development, functional genomics, and cell and gene therapy. Previously Steve led the Screening Sciences department with accountability for Compound Management, Hit Discovery and Lead Optimisation biology. Prior to joining AstraZeneca, Steve worked at GlaxoSmithKline for 24 years. He has served as Chair of the European Laboratory Research and Innovation Group and Chair of the European council of the Society of Laboratory Automation and Screening, and is Industry Trustee of the British Pharmacological Society. Steve was awarded an OBE in 2021 for services to science and the COVID19 response.

Dr Amaury Fernández-Montalván
Boehringer ingelheim

Amaury E. Fernández-Montalván is Director of High Throughput Biology (HTB) in Boehringer Ingelheim’s R&D site in Biberach, Germany since August 2020. He previously served for 2+ years as Head of Compound Screening at the SERVIER Research Institute in Croissy-sur-Seine, France. Between 2008 and 2018 he worked as Head of Laboratory in the Assay Development and High Throughput Screening Group of Bayer’s Lead Discovery Unit in Berlin. Before joining Bayer, he trained as postdoctoral research fellow at the Expertise Platform Proteases of the Novartis Institutes of Biomedical Research in Basel (2005-2006), and the Molecular Pharmacology and Compound Screening Department of Merck Serono International S.A. in Geneva (2007-2008). Amaury studied Biochemistry at the University of Havana and obtained his PhD from the Technical University of Munich in 2004. During his career in the pharmaceutical industry, he has been involved as team member and leader of multiple drug discovery programs from early to clinical stages. His main contributions to these projects were the development and execution of biochemical and biophysical screening assays for hit identification campaigns, as well as for compound profiling activities during the hit-to-lead and lead optimization phases. His research has led to the identification of several chemical probes and clinical candidates, as well as to more than 60 patent applications and peer reviewed scientific publications. His current scientific interests include the use of high throughput screening methodologies for the characterization of drug - target interactions and the exploitation of the information generated with chemo informatics and quantitative system pharmacology tools.

Dr Andrea Gohlke
Associate Principal Scientist, AstraZeneca

Dr. Andrea Gohlke is an Associate Principal Scientist in Biophysics working within the Mechanistic and Structural Biology department at AstraZeneca in Cambridge, UK.
She joined AstraZeneca in 2019 and is using Biophysics in early- stage cancer drug discovery providing essential information about binding kinetics and the mode of action. In addition, she is a project leader including new capability developments.
Starting her scientific career, she studied Molecular Life Science and obtained her PhD in Biophysical Chemistry at TU Dortmund in Germany in conjunction with the Max Planck Institute for Molecular Physiology in 2010. Here, she biophysically characterised the interaction of amyloids and small GTPases with model membranes and cells and how these can be modified.
After that, she worked as postdoc in the group of Nobel laureate James Rothman at Yale University (USA) as well as at the École Normale Supérieure (France) studying SNARE-mediated membrane fusion using model membranes. Her work has been acknowledged with a postdoctoral fellowship from the German Research foundation.
In 2015 she joined the Drug Discovery Programme at the CRUK Beatson institute (UK) where she used Biophysics in early-stage cancer drug discovery as well as lead collaborations with academic institutions.
Her general scientific focus is the biophysical characterisation of protein/ligand interactions using a range of spectroscopic and microscopic methods. She is also a member of the publication committee of the Biophysical Journal.

Dr Stefan Geschwindner
Director Biophysics, AstraZeneca

Dr. Stefan Geschwindner is currently a Director at AstraZeneca R&D Gothenburg in Sweden where he is heading the Biophysics department within Discovery Sciences. He obtained his Ph.D. at the University of Frankfurt working predominantly with NMR to elucidate protein structures. After his Ph.D. he joined the Astra Structural Chemistry Laboratory with focus on protein engineering and characterization and helped to implement a variety of different biophysical methods. Before moving into his current role, he had different roles as Team leader in Protein Engineering and as Principal Scientist in Biophysics. During the last two decades, he has frequently applied biophysical methods to facilitate the mechanistic understanding of protein-ligand interactions and their kinetcis and to enable fragment-based lead generation approaches. Furthermore, he has authored/co-authored over 50 publications, book chapters and patents dealing with and demonstrating the impact of biophysical approaches in drug discovery.

Dr Geoff Holdgate
Senior Principal Scientist, AstraZeneca

Geoff joined AstraZeneca’s predecessor ICI in 1992. He was responsible for establishing Isothermal Titration Calorimetry and Surface Plasmon Resonance into Zeneca in the mid-1990s. Geoff has led both molecular enzymology and biophysics teams and more recently the HTS department, before being promoted to Senior Principal Scientist in Hit Discovery in 2021. Geoff has contributed to discovery of several marketed drugs including Iressa, Crestor, Caprelsa, Koselugo and Tagrisso. He has contributed to over 40 original research articles, reviews and book chapters, with an h-index of 28. He sits on the editorial boards for ADMET & DMPK and SLAS Discovery. Geoff is a regular reviewer for journals including Scientific Reports, J. Med. Chem., Drug Discovery Today, Biochemical Pharmacology and European Biophysics Journal. In 2017 he was awarded the SLAS Reviewer Excellence Award and has recently been elected a Fellow of SLAS. Geoff regularly organises and presents at external meetings including the ELRIG Discovery Technologies meetings and the Next Generation Biophysics Meeting.


Dr Thomas Lundback
Senior Director, AstraZeneca

Dr. Thomas Lundbäck joined the Discovery Sciences organisation as Associate Director in 2016, transitioning into his current role in 2022. In this role, he is responsible for a team that provides world-class SAR profiling and bespoke mechanism of action studies in support of drug discovery projects across multiple drug modalities. This organization, based in Gothenburg, primarily serves the Cardiovascular, Renal, and Metabolism, as well as Respiratory and Immunology therapy areas.

Thomas has more than 25 years of experience in life science research, including several transitions between academia and industry. He received his PhD in biophysics at the Karolinska Institutet, and following postdoctoral studies at University College London and Yale University, he joined Pharmacia & Upjohn in 1999, where he spent 10 years. Prior to joining AstraZeneca, Thomas was back at the Karolinska Institutet, supporting the Chemical Biology Consortium Sweden (CBCS), a national infrastructure for chemical biology research. It is in this setting that he encountered the cellular thermal shift assay (CETSA) and played a key role in the addition of HTS-compatible readouts to the Pelago Bioscience patent portfolio.

Thomas brings a rich external network, which he leverages as an experienced organizer of scientific meetings, with the ELRIG Advances in Cell-Based Screening meeting as a key 2022 highlight. Additional external roles include his service as chairman of the steering groups for CBCS and the Chemical Biology and Genome Engineering platform at SciLifeLab, a member of the ELRIG Science Strategy Committee, and the Industry Liaison Office for the EU-OPENSCREEN DRIVE project. Thomas is also an Associate Editor of the ASSAY and Drug Development Technologies journal.

Dr Argyrides Argyrou
Associate Principal Scientist, AstraZeneca

Argyrides (Archie) joined the Biochemical Assay Development team of AstraZeneca as an Associate Principal Scientist in 2016. Previously, he worked as a Senior Research Investigator in the Chemical Enzymology Department at Bristol-Myers Squibb, Co. in Pennington, NJ (2006 – 2009) and he managed Biological Reagent, Assay Development and Enzymology teams at GlaxoSmithKline in Stevenage, UK (2010 – 2016).

Archie obtained his PhD degree in Biochemistry from The Johns Hopkins University in Baltimore, MD in the lab of Cecile M. Pickart studying Non-enzymatic and Enzymatic Mechanisms of Proton Transfer from carbon and post-doc training in Mechanistic Enzymology and Chemical Biology of Mycobacterium tuberculosis drug targets in the lab of John S. Blanchard at the Albert Einstein College of Medicine in Bronx, NY.

In his industrial career, Archie has worked on a wide variety of drug targets in multiple therapy areas using his mechanistic enzymology and kinetics expertise to develop biochemical platforms and to help advance projects. He has established successful external collaborations, he has served on Scientific Advisory Boards for GSK/Dundee DDU and for the National Physical Laboratory, he sits on Editorial Boards for ACS Infectious Diseases and Frontiers and has authored over 30 publications.



Download our Partnerships Prospectus to see the packages on offer. 

If you are interested in partnering with us, please get in touch by contacting today to discuss how we can work together.


Enzymlogic is a specialist CRO, providing kinetic profiling services for small molecule drug discovery with unparalleled speed and efficiency. We facilitate the screening of reversible and irreversible inhibitors in early discovery to iterate Med Chem, understand PK PD disconnects and build better models to define therapeutic windows.


AssayQuant supports the drug discovery process and enables the development of more effective therapies targeting kinase and phosphatase enzyme activity. Their novel PhosphoSens® technology provides direct and continuous quantitative monitoring of phosphorylation or dephosphorylation in a simple add-and-read format, yielding a progress curve in every well for deep enzymological characterization.

Applied Photophysics

Applied Photophysics of Leatherhead, Surrey, UK, is a leading provider of solutions for the biophysical characterisation of biomolecules and has been providing spectroscopy to the research community for over 50 years. Chirascan™ systems use the phenomenon of circular dichroism (CD) to characterise changes in the higher-order structure of proteins. The company’s SX range of stopped-flow spectrometers is acknowledged globally as the gold standard for kinetic studies of fast biochemical reactions.

British Journal of Pharmacology

The British Journal of Pharmacology (BJP) is a broad-based journal giving leading international coverage of all aspects of experimental pharmacology. It publishes high quality original research and authoritative reviews. BJP is published fortnightly, and is available online.

Poster Presenters

PP01 - Sarah Folliet
FRET association binding kinetics for accurate probe characterisation
PP02 - Mario Giorgi
A Quantitative Systems Pharmacology (QSP) model of the Arachidonic Acid (AA) metabolic network to explore the heterogeneity of Inflammatory Bowel Disease (IBD)
PP03 - Clare Harwood
Agonist efficacy at the β₂AR is driven agonist induced conformational differences that increase the affinity of the β₂AR for the Gs protein.
PP04 - Roshan Sahu
Interactome and metabolome analysis of Cannabinoids receptors- A mechanistic approach & links to their PK/PD
PP05 - Nicola Dijon
Using HiBiT stabilization to determine agonist binding kinetics at active β₂AR-mGαs complexes.
PP06 - Carsten Hoffmann
Real-time allosteric modulation at human and rat adenosine A1 receptor
PP07 - Francine van der Graaf
Early de-risking of cardiac safety liability: evaluation of an in vitro assay for binding kinetics against the human ether-a-go-go-related (hERG) channel
PP08 - Lloyd Bridge
Theoretical and practical results from low-dimensional mathematical models for binding kinetics, signal transduction dynamics and pharmacokinetics
PP09 - Wilbert de Witte
Using physiological knowledge to predict the koff-dependent occupancy in tissues
PP10 - Philip Pickford
Analysis of the initial velocity of calcium signalling and β-arrestin recruitment at GPR55 with different activators shows unique signalling profiles
PP12 - Aurélien Rizk
Mathematical models of GPCR signaling to remove kinetic dependency in signaling bias quantification
PP14 - Josephus Buijs
Binding kinetics on live cells unravels how epitope binding influences antibody dependent complement engagement for therapy of B-cell malignancies
PP15 - Daren Austin
The clinical PKPD translation of in vitro viral neutralisation is impacted by intrinsic viral dynamics rather than antibody binding characteristics
PP16 - Léopold Thabault
Benefits of structural and biophysical methods for DEL-based projects in early drug discovery
PP17 - Antonio Jesús Ortiz García
Modelling time-dependent binding and function of GPCR heterodimers: towards mechanism-based drug combination therapies
PP19 - Thomas Williams
Mining the 100,000 Genomes Project and X-ray crystal structure to identify, characterise, and rescue loss-of-function apelin receptor variants
PP20 - Emma Murphy
High-Throughput Kinetic Characterisation of USP30 Inhibitors
PP21 - Cornelius Trünkle
Studying the effects of lysosomal compound distribution on prolonged target engagement using in vitro and in silico tools

Organising Committee 


Bharath Srinivasan
Principal Scientist, AstraZeneca, UK 

Bharath Srinivasan is a Principal Scientist at the Mechanistic and Structural Biology unit, Discovery Sciences, AstraZeneca, contributing actively to several oncology projects deducing the MoA of small-molecule leads. Bharath has published around 38 peer-reviewed publications, 1 patent and several science outreach articles. He is editor with two prominent pharmacology journals ( British Journal of Pharmacology and Current opinion in Pharmacology), a faculty with faculty opinions and on the editorial advisory board of FEBS J. Additionally, he is an ambassador for the British Pharmacological Society and the Biochemical Society. He is passionate about enzyme kinetics with particular emphasis on studying the spatio-temporal evolution of kinetic systems, steady state kinetics, pre-steady state kinetics, single turnover kinetics and non-Michaelian kinetics. Bharath is also invested heavily in optimizing methods for in-cellulo kinetics and label-free detection methods.


Jonathan Wingfield
Principal Scientist, AstraZeneca, UK 

Jonathan Wingfield has nearly 30 years’ experience working in early drug discovery within Pharma. After joining AstraZeneca in 2000 as part of the Oncology department he led several successful projects to drive up the quality of data generation within the department. He established a centralised biochemical screening capability to support Oncology projects. Jonathan is an active member of the Society for Laboratory Automation and Screening (SLAS) and has contributed to their journals and guest edited a special edition on Mass Spectrometry in early drug discovery. He is now a board member of SLAS and will take on the role of Vice President from January 2023. Jonathan is passionate about technology and its application in drug discovery and committed to the education of the next generation of scientists.


Professor Cherry Wainwright
Deputy Vice President, British Pharmacological Society, UK 

Cherry graduated from the University of Aberdeen with a BSc (Hons) in Pharmacology and subsequently the University of Strathclyde with a PhD in Cardiovascular Pharmacology. She is a Fellow of the British Pharmacological Society and the Higher Education Academy, and a member of the IUPHAR Natural Products Section Committee. Cherry spent over 20 years at Strathclyde as an academic involved in both teaching and research, before moving to the Robert Gordon University in Aberdeen in 2003 as a Research Professor, where she spent 8 years as the Director of the multi-disciplinary Institute for Health & Wellbeing Research (2007-2015). She is now the lead in Cardiometabolic Health Research and Co-Director of the Centre for Natural Products in Health, which focuses on the identification of novel pharmaceutical and nutraceutical agents from plant, marine algal and food processing waste-derived sources. Throughout her career Cherry’s research has focused on mechanisms underlying the pathophysiology and the identification of novel therapeutic targets of cardiovascular diseases; and one of the main threads has been the evaluation of the role of endogenous biological mediators as both the perpetrators of, and protective substances against, cardiovascular disorders. For the last 16 years her emphasis has been on the role of the endocannabinoid system in cardiac (ischaemia/reperfusion) and vascular (atherosclerosis, restenosis) injury and energy regulation in the cardiovascular system. Her seminal paper on the cardioprotective effects of CBD opened up her current research programme that focuses on the role of the putative cannabinoid receptor GPR55 in regulating cardiovascular physiology and pathophysiology and the role this receptor plays in the relationship between obesity, metabolic syndrome and the development of cardiovascular disorders. Cherry has published over 90 full original articles, 200 conference proceedings, 7 invited reviews, 6 book chapters, edited one book and prepared 20 unpublished reports to industry. She also has 3 patent applications and has given over 30 invited symposium lectures.

Educational resources and background literature
Binding Kinetics and Mechanistic PK/PD modelling is emerging as an essential part of early drug discovery optimisation decisions. This page includes links to essential literature authored by the speakers and organisers that will shed increased light on the role of these and show the evolution of this field. Any interested delegate is encouraged to go through these works to gain an understanding on the discourse that will be undertaken as part of this meeting. 

MICE Concierge 


MICE Concierge is the official accommodation partner for Binding Kinetics and Mechanistic PK/PD modeling in early Drug Discovery and will take care of your accommodation requirements during your visit to Cambridge. The official delegate hotels are:

Hyatt Centric Cambridge (4 star) which is located a short 14 minute walk from the Moller Institute
IBIS Hotel (3 star) which is a 30 minute bus ride to the venue

To make your booking with MICE Concierge please visit their booking platform

Alternatively, the Moller Institute also have onsite accommodation. To make a booking at the venue, please call and speak to reception on 01223 465 500 or submit an enquiry though the website and a member of the team will contact you.

The Møller Institute

Churchill College, Storey's Way, Cambridge CB3 0DE

The Møller Institute

For directions and information on the location please visit The Møller Institute's website

View details about the venue's guest relations and services.

The Mærsk Mc-Kinney Møller Institute was built with a donation from the A.P. Møller Foundation, a Danish institution which makes contributions to causes involving national heritage, shipping, industry and science. It was opened in 1992 by Her Majesty Queen Ingrid of Denmark and is a world-class, dedicated residential leadership development Institute at Churchill College, University of Cambridge.

The main building was designed by a Danish Architect, Henning Larsen, and resembles a ship, with the tower acting as the propeller, and the Lecture Theatre as the bridge. The dominating element of the Institute is the octagonal tower – from the terrace on the top there is an incredible panoramic view over the city of Cambridge.

The Møller Institute is located within the beautiful 42 acre grounds of Churchill College, University of Cambridge and is less than an hour away from London.


The Society wishes to make sure all our events are inclusive and accessible to everyone and will work with our venues and suppliers to support attendees where possible. During registration, please let us know of any access requirements you or your guests have, and we will do our best to accommodate. If you would prefer to speak to a member of staff or need assistance in planning your time at one of our events, please contact or +44 (0) 20 7239 0183.

Special themed issue submissions

British Journal of Pharmacology will be publishing a special ‘Themed Issue’ entitled: Binding Kinetics and Mechanistic PK/PD modelling in early Drug Discovery, with Bharath Srinivasan, and Sam Hoare as Guest Editors.

In this issue on, Binding Kinetics and Mechanistic PK/PD modelling in early Drug Discovery we will provide an up-to-date account of/ on the use of binding kinetics and mechanistic PK/PD modelling in informing early drug discovery decisions. This issue will strive to delve deeper into the importance of aspects like association, dissociation, rebinding and residence time of target-small molecule interactions. Additionally, it will shed critical light on the role of binding kinetics, target vulnerability, protein turnover and uptake/efflux of the small-molecule in modelling target occupancy metrics.

The issue will include authoritative state of the art review articles from
Dr Bob Copeland (President, Co-founder and Chief Scientific Officer, Accent): Overview of the importance of binding kinetics with special emphasis on dissociation rate and residence time.
Professor Peter Tonge (Brook University): Importance of mechanistic PK/PD modelling in early drug discovery.
Professor Adriaan Ljzerman (Leiden University ): Importance of association in drug-target interaction.
Professor Steve Charlton (University of Nottingham & Vice President, OMass Therapeutics): Importance of drug rebinding in drug target interaction
Professor Steve Hill (University of Nottingham ): Overview of approaches that will allow in-cellulo interrogation of drug target kinetics with special emphasis on BRET

Deadline for submissions is 31 May 2023.

Click here for more information.

27 March 2023
07 November 2023
9.30am BST to 5pm BST
Delivery Method

Connect with us:

© 2021 British Pharmacological Society, The Schild Plot, 16 Angel Gate, City Road, London EC1V 2PT, United Kingdom